Rabeprazole Sodium Tablet, Delayed Release
Product Images NDC 68788-8536

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 68788-8536). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Image (Rabeprazole Dr Tablet 01)

Chemical structure diagram of rabeprazole sodium, the active ingredient in RABEPRAZOLE SODIUM delayed-release tablets.*

FDA Label Image

Figure 2: Mean Daytime Heartburn Scores Rab-usa-2 (Rabeprazole Dr Tablet 02)

A line graph showing mean heartburn scores over a study period of 28 days, comparing placebo and rabeprazole sodium doses of 10 mg and 20 mg. The x-axis represents study days from -14 to 28, with a vertical line at day 0 indicating treatment start. The y-axis shows mean heartburn scores from 0 (none) to 4 (very severe).*

FDA Label Image

Figure 3: Mean Nighttime Heartburn Scores Rab-usa-2 (Rabeprazole Dr Tablet 03)

A line graph showing mean heartburn scores over a study period from day -14 to day 28. It compares three groups: placebo (dashed line), rabeprazole 10 mg (dotted line), and rabeprazole 20 mg (solid line). The x-axis represents study days, and the y-axis represents heartburn severity scores from 0 (none) to 4 (very severe).*

FDA Label Image

Figure 4: Mean Daytime Heartburn Scores Rab-usa-3 (Rabeprazole Dr Tablet 04)

A line graph comparing mean heartburn scores over time between a placebo group (n=58) and a group receiving 20 mg rabeprazole sodium (n=59). The x-axis represents study days from -14 to 28, and the y-axis shows heartburn severity scores from 0 (none) to 4 (very severe). Scores for the rabeprazole group decrease more notably after study day 0 compared to placebo.*

FDA Label Image

Figure 5: Mean Nighttime Heartburn Scores Rab-usa-3 (Rabeprazole Dr Tablet 05)

A line graph depicting mean heartburn scores over a 28-day study period comparing placebo and rabeprazole sodium 20 mg groups. The x-axis shows study days from -14 to 28, and the y-axis shows mean heartburn scores ranging from 0 (none) to 4 (very severe). Two lines represent placebo (dotted) and rabeprazole 20 mg (solid).*

FDA Label Image

Rabeprazole Sodium Delayed-release Tablets 20mg (Rabeprazole Dr Tablet 30s Label)

Label for Rabeprazole Sodium Delayed-Release Tablets 20 mg by Preferred Pharmaceuticals Inc., generic for Aciphex. The label states each tablet contains 20 mg rabeprazole sodium. Manufacturer is Rubicon Research Private Limited. The label features dosage directions in English and Spanish on a yellow background and includes cautionary storage and prescription warnings.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.